表紙
市場調査レポート

臍帯血幹細胞の世界市場:2015年〜2019年

Global Stem Cell Umbilical Cord Blood Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 337795
出版日 ページ情報 英文 79 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
臍帯血幹細胞の世界市場:2015年〜2019年 Global Stem Cell Umbilical Cord Blood Market 2015-2019
出版日: 2015年08月19日 ページ情報: 英文 79 Pages
概要

世界の臍帯血 (UCB) 幹細胞市場は、2014年〜2019年のCAGRで、30.36%の成長が見込まれています。

当レポートでは、世界の臍帯血幹細胞市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 臍帯血 (UCB) 細胞の採取・処理・保管のプロセス

  • ドナー評価
  • 採取方法
  • 処理・保管方法
  • サンプル保持・保管期間

第7章 ファクト:臍帯血

第8章 米国のFDAが認可した臍帯血幹細胞製品

  • Hemacord

第9章 パイプライン分析

  • パイプライン候補に関する情報

第10章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第11章 市場区分:応用別

  • がん
  • 血液疾患
  • 代謝疾患
  • 免疫疾患
  • その他

第12章 市場区分:保管別

  • 公的バンク
  • 私的バンク
  • 官民バンク

第13章 バイオバンクの調和

第14章 市場区分:エンドユーザー別

  • 研究機関
  • 製薬会社
  • バイオバンク
  • 病院

第15章 地理区分

  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第16章 購入基準

第17章 市場成長促進要因

第18章 成長促進要因とその影響

第19章 市場の課題

第20章 成長促進要因と課題の影響

第21章 市場動向

第22章 動向とその影響

第23章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他・将来有望なベンダー

第24章 世界の臍帯血幹細胞市場:要点

第25章 主要ベンダー分析

  • Caladrious
  • Celgene
  • Mesoblast
  • Pluristem

第26章 関連レポート

図表

目次
Product Code: IRTNTR6649

About Stem Cell UCB

UCB is the blood that remains in the placenta and the attached umbilical cord after childbirth. UCB contains stem cells that are unique, smart, and are capable of treating several life-threatening diseases. They are used in the treatment of hematopoietic and genetic disorders. The placental blood can produce 10 times more quantity of stem cells compared to the umbilical cord, which can in turn be used for the treatment of an adult patient. The cord blood that is collected during the childbirth is stored and cryopreserved. The storage of the cord blood can be done at private cord blood banks or public cord blood banks. This preserved blood can be used for the transplantation, and treatment of diseases at the later stages of life.

Technavio's analysts forecast the global stem cell UCB market to grow at a CAGR of 30.36% over the period 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global stem cell UCB market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the banking and utilization of UCB stem cells for the treatment of various disorders, such as cancers, blood disorders, metabolic disorders, immune diseases, and others.

Technavio's report, Global Stem Cell UCB Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global stem cell UCB market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Caladrius Biosciences
  • Celgene
  • Mesoblast
  • Pluristem Therapeutics

Other Prominent Vendors

  • Athersys
  • CHA Bio & Diostech
  • Cytori Therapeutics
  • Nuo Therapeutics
  • Ocata Therapeutics
  • Opexa Therapeutics
  • Osiris Therapeutics
  • Teva Pharmaceuticals
  • United Therapeutics

Key Market Driver

  • Effective Treatment of Life-threatening Diseases
  • For a full, detailed list, view our report

Key Market Challenge

  • Stringent Regulations
  • For a full, detailed list, view our report

Key Market Trend

  • Growing Public Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Process of Collection, Processing, and Storage of Cord Blood Cells

  • 06.1. Donor Evaluation
  • 06.2. Collection Methods
  • 06.3. Processing and Storage Methods
  • 06.4. Sample Retention and Length of Storage

07. Facts: Cord Blood Units

08. US FDA Approved Stem Cell UCB Product

  • 08.1. Hemacord
    • 08.1.1. Mechanism of Action
    • 08.1.2. Side Effects

09. Pipeline Analysis

  • 09.1. Information on Pipeline Candidates
    • 09.1.1. PDA-002
    • 09.1.2. PDA-001
    • 09.1.3. PLX-PAD
    • 09.1.4. PLX-R18

10. Market Landscape

  • 10.1. Market Overview
  • 10.2. Market Size and Forecast
  • 10.3. Five Forces Analysis

11. Market Segmentation by Application

  • 11.1. Cancers
  • 11.2. Blood Disorders
  • 11.3. Metabolic Disorders
  • 11.4. Immune Disorders
  • 11.5. Others

12. Market Segmentation by Storage

  • 12.1. Public Cord Blood Bank
  • 12.2. Private Cord Blood Bank
  • 12.3. Public-Private Cord Blood Banks

13. Harmonization of Biobanking

14. Market Segmentation by End-user

  • 14.1. Research Institutes
  • 14.2. Pharmaceutical Companies
  • 14.3. Biobanks
  • 14.4. Hospitals

15. Geographical Segmentation

  • 15.1. Stem Cell UCB Market in Americas
    • 15.1.1. Market Size and Forecast
  • 15.2. Stem Cell UCB Market in EMEA
    • 15.2.1. Market Size and Forecast
  • 15.3. Stem Cell UCB Market in APAC
    • 15.3.1. Market Size and Forecast

16. Buying Criteria

17. Market Growth Drivers

18. Drivers and their Impact

19. Market Challenges

20. Impact of Drivers and Challenges

21. Market Trends

22. Trends and their Impact

23. Vendor Landscape

  • 23.1. Competitive Scenario
    • 23.1.1. Key News
    • 23.1.2. Mergers and Acquisitions
  • 23.2. Market Share Analysis 2014
    • 23.2.1. Caladrius Biosciences
    • 23.2.2. Celgene Corp.
    • 23.2.3. Mesoblast Ltd.
    • 23.2.4. Pluristem Therapeutics
  • 23.3. Other and Future Prominent Vendors

24. Global Stem Cell UCB Market: Key Takeaways

25. Key Vendor Analysis

  • 25.1. Caladrious
    • 25.1.1. Key Facts
    • 25.1.2. Business Overview
    • 25.1.3. Business Segmentation by Revenue 2014
    • 25.1.4. Business Segmentation by Revenue 2013 and 2014
    • 25.1.5. Geographical Segmentation by Revenue 2014
    • 25.1.6. Business Strategy
    • 25.1.7. Recent Developments
    • 25.1.8. SWOT Analysis
  • 25.2. Celgene
    • 25.2.1. Key Facts
    • 25.2.2. Business Overview
    • 25.2.3. Business Strategy
    • 25.2.4. Business Segmentation by Revenue
    • 25.2.5. Sales by Geography
    • 25.2.6. Key Information
    • 25.2.7. SWOT Analysis
  • 25.3. Mesoblast
    • 25.3.1. Key Facts
    • 25.3.2. Business Overview
    • 25.3.3. Therapeutic Areas
    • 25.3.4. Geographical Segmentation
    • 25.3.5. Business Strategy
    • 25.3.6. Recent Developments
    • 25.3.7. SWOT Analysis
  • 25.4. Pluristem
    • 25.4.1. Key Facts
    • 25.4.2. Business Overview
    • 25.4.3. Geographical Presence
    • 25.4.4. Business Strategy
    • 25.4.5. Recent Developments
    • 25.4.6. SWOT Analysis

26. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Donor Evaluation before Collection of Cord Blood Cells
  • Exhibit 3: Collection of Cord Blood Cells
  • Exhibit 4: Processing and Storage Methods of Cord Blood Cells
  • Exhibit 5: Stem Cell Transplantations by Patient Race in US
  • Exhibit 6: Pipeline Portfolio of Stem Cell UCB Products for Different Diseases
  • Exhibit 7: Global Stem Cell UCB Market 2014-2019 ($ millions)
  • Exhibit 8: Global Stem Cell UCB Market Segment by Application
  • Exhibit 9: Global Stem Cell UCB Market Segmentation by Storage
  • Exhibit 10: Organizations and Initiatives Toward Biobank Harmonization
  • Exhibit 11: Key Factors Involved in Harmonization of Biobanks
  • Exhibit 12: Key Focus Areas in Harmonization of Biobanks
  • Exhibit 13: Organizations and Initiatives in Harmonizing Science and Infrastructure
  • Exhibit 14: Initiatives on Biobanking Resource Tools and Databases
  • Exhibit 15: Global Stem Cell UCB Market Segment by End-user
  • Exhibit 16: Segmentation of Global Stem Cell UCB Market by Geography 2014
  • Exhibit 17: Stem Cell UCB Market in Americas 2014-2019 ($ millions)
  • Exhibit 18: Stem Cell UCB Market in APAC 2014-2019 ($ millions)
  • Exhibit 19: Stem Cell UCB Market in APAC 2014-2019 ($ millions)
  • Exhibit 20: Statistics of Stem Cell UCB Market by Geography
  • Exhibit 21: Global Stem Cell UCB Market: Key Takeaways
  • Exhibit 22: Caladrious: Business Segmentation by Revenue 2014
  • Exhibit 23: Caladrious: Business Segmentation by Revenue 2013 and 2014 ($ millions)
  • Exhibit 24: Caladrious: Geographical Segmentation by Revenue 2014
  • Exhibit 25: Celgene: Business Segmentation by Revenue 2011-2013 ($ millions)
  • Exhibit 26: Celgene: Sales by Geography 2013
  • Exhibit 27: Mesoblast: Therapeutic Areas
  • Exhibit 28: Mesoblast: Geographical Segmentation
  • Exhibit 29: PLuristem: Geographical Presence
Back to Top